vs
百特国际（BAX）与GFL Environmental Inc.（GFL）财务数据对比。点击上方公司名可切换其他公司
GFL Environmental Inc.的季度营收约是百特国际的1.7倍（$4.9B vs $3.0B），GFL Environmental Inc.净利率更高（-13.9% vs -37.9%，领先24.0%）
百特国际是总部位于美国伊利诺伊州迪尔菲尔德的跨国医疗健康企业，业务布局覆盖全球众多市场，专注于研发、生产及销售各类医疗相关产品与解决方案，为全球医疗机构和患者提供专业可靠的医疗支持。
GFL Environmental Inc.是美加跨国废弃物管理企业，2007年成立于加拿大安大略省沃恩市，现总部设于美国佛罗里达州迈阿密海滩。公司业务覆盖加拿大所有省份及美国大部分区域，现有员工超2万人，面向市政、住宅、工商业及机构客户提供专业环境服务。
BAX vs GFL — 直观对比
营收规模更大
GFL
是对方的1.7倍
$3.0B
净利率更高
GFL
高出24.0%
-37.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.0B | $4.9B |
| 净利润 | $-1.1B | $-686.1M |
| 毛利率 | 19.4% | — |
| 营业利润率 | -24.5% | — |
| 净利率 | -37.9% | -13.9% |
| 营收同比 | 458.0% | — |
| 净利润同比 | -120.3% | — |
| 每股收益（稀释后） | $-2.21 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BAXGFL
| Q4 25 | $3.0B | — | ||
| Q3 25 | $2.8B | $4.9B | ||
| Q2 25 | $2.8B | $3.2B | ||
| Q1 25 | $2.6B | $1.6B | ||
| Q4 24 | $533.0M | — | ||
| Q3 24 | $2.7B | $5.9B | ||
| Q2 24 | $3.8B | $3.9B | ||
| Q1 24 | $3.6B | $1.8B |
净利润BAXGFL
| Q4 25 | $-1.1B | — | ||
| Q3 25 | $-46.0M | $-686.1M | ||
| Q2 25 | $91.0M | $-727.7M | ||
| Q1 25 | $126.0M | $-195.8M | ||
| Q4 24 | $-512.0M | — | ||
| Q3 24 | $140.0M | $94.3M | ||
| Q2 24 | $-314.0M | — | ||
| Q1 24 | $37.0M | $-217.8M |
毛利率BAXGFL
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | — | ||
| Q1 24 | 38.6% | — |
营业利润率BAXGFL
| Q4 25 | -24.5% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | 5.7% | — | ||
| Q2 24 | -5.0% | — | ||
| Q1 24 | 5.2% | — |
净利率BAXGFL
| Q4 25 | -37.9% | — | ||
| Q3 25 | -1.6% | -13.9% | ||
| Q2 25 | 3.2% | -22.5% | ||
| Q1 25 | 4.8% | -12.6% | ||
| Q4 24 | -96.1% | — | ||
| Q3 24 | 5.2% | 1.6% | ||
| Q2 24 | -8.2% | — | ||
| Q1 24 | 1.0% | -12.1% |
每股收益（稀释后）BAXGFL
| Q4 25 | $-2.21 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $0.25 | — | ||
| Q4 24 | $-0.99 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $-0.62 | — | ||
| Q1 24 | $0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | — |
| 总债务越低越好 | $9.5B | — |
| 股东权益账面价值 | $6.1B | — |
| 总资产 | $20.1B | — |
| 负债/权益比越低杠杆越低 | 1.55× | — |
8季度趋势，按日历期对齐
现金及短期投资BAXGFL
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $3.0B | — |
总债务BAXGFL
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
股东权益BAXGFL
| Q4 25 | $6.1B | — | ||
| Q3 25 | $7.2B | — | ||
| Q2 25 | $7.3B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $7.9B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $8.2B | — |
总资产BAXGFL
| Q4 25 | $20.1B | — | ||
| Q3 25 | $21.1B | — | ||
| Q2 25 | $21.0B | — | ||
| Q1 25 | $21.3B | — | ||
| Q4 24 | $25.8B | — | ||
| Q3 24 | $26.7B | — | ||
| Q2 24 | $26.3B | — | ||
| Q1 24 | $27.8B | — |
负债/权益比BAXGFL
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $584.0M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BAXGFL
| Q4 25 | $584.0M | — | ||
| Q3 25 | $237.0M | — | ||
| Q2 25 | $217.0M | — | ||
| Q1 25 | $-193.0M | — | ||
| Q4 24 | $488.0M | — | ||
| Q3 24 | $253.0M | — | ||
| Q2 24 | $115.0M | — | ||
| Q1 24 | $163.0M | — |
现金转化率BAXGFL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.38× | — | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
GFL
暂无分部数据
